• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

AlzeCure Pharma

6.16 SEK-2.84 %10.7. klo 18.29
Less than 1K followers

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.84 %
+46.53 %
+376.85 %
+265.38 %
+251.67 %
+158.58 %
+43.76 %
-6.83 %
-25.72 %

AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.

Read more
Market cap
849.45M SEK
Turnover
2.54M SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
26.8.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

23.2.
2027

Annual report '26

Regulatory press release02.07.2026 klo 09.00

Final outcome of AlzeCure’s rights issue

AlzeCure Pharma
Regulatory press release01.07.2026 klo 08.00

AlzeCure Pharma enters an out-licensing and collaboration agreement with QuantumCell ApS for the NeuroRestore ACD856 project

AlzeCure Pharma
Regulatory press release29.06.2026 klo 18.30

Communiqué from the annual general meeting of AlzeCure Pharma on 29 June 2026

AlzeCure Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release16.06.2026 klo 11.00

Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's

AlzeCure Pharma
Regulatory press release16.06.2026 klo 09.00

The subscription period in AlzeCure Pharma's Rights Issue begins today

AlzeCure Pharma
Press release10.06.2026 klo 13.58

Redeye: AlzeCure Pharma: From lab to Lilly – A historic USD1bn validation

AlzeCure Pharma
Regulatory press release09.06.2026 klo 08.10

AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project

AlzeCure Pharma
Regulatory press release05.06.2026 klo 09.00

AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document

AlzeCure Pharma
Regulatory press release26.05.2026 klo 09.00

NOTICE TO ANNUAL GENERAL MEETING IN AlzeCure Pharma AB

AlzeCure Pharma
Press release19.05.2026 klo 11.00

AlzeCure Pharma to host live seminar on the pain project TrkA-NAM ACD137 with a focus on osteoarthritis and neuropathic pain

AlzeCure Pharma
Press release13.05.2026 klo 13.00

AlzeCure Pharma to present at Redeye Investor Forum Online on May 21

AlzeCure Pharma
Press release13.05.2026 klo 11.00

AlzeCure Pharma to present at ABG Investor Days on May 21

AlzeCure Pharma
Press release08.05.2026 klo 11.16

Redeye: AlzeCure Pharma (Q1 Review): Advancing toward Phase IIa with NeuroRestore ACD856

AlzeCure Pharma
Press release06.05.2026 klo 11.00

New scientific article published on TrkA-NAM ACD137 against osteoarthritic pain

AlzeCure Pharma
Regulatory press release05.05.2026 klo 09.00

AlzeCure publishes its interim report for January – March 2026

AlzeCure Pharma
Regulatory press release30.04.2026 klo 09.00

Adjusted timeline for the previously communicated rights issue

AlzeCure Pharma
Regulatory press release24.04.2026 klo 09.00

AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million

AlzeCure Pharma
Press release20.04.2026 klo 11.00

Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856

AlzeCure Pharma
Regulatory press release08.04.2026 klo 09.00

AlzeCure Pharma publishes its Annual Report for 2025

AlzeCure Pharma
Press release07.04.2026 klo 11.00

AlzeCure Pharma to present at Redeye Healthcare Day on April 14

AlzeCure Pharma